Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significant Cardiac Rhythm Disturbances in Infant Bronchiolitis: A Holter-Based Prospective Analysis.

Journal of pediatrics. Clinical practice·2026
Same author

Transeptal Mitral Annuloplasty With the AMEND System: 6-Month Results of First in Man Cohort.

Circulation. Cardiovascular interventions·2026
Same author

Discharge Opioid Prescriptions Following Pediatric Appendectomy: A NSQIP-P Study.

Journal of pediatric surgery·2025
Same author

A National Study of Travel and Nontravel Nurses' Perceptions of the Work Environment.

The Journal of nursing administration·2025
Same author

Transseptal Mitral Annuloplasty With the AMEND System: 30-Day Results.

JACC. Cardiovascular interventions·2025
Same author

Effect of multiple births on cardiac status of women with congenital heart disease: A matched case-controlled study.

International journal of cardiology. Congenital heart disease·2024

Related Experiment Video

Updated: Jun 14, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
10:52

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence

Published on: December 23, 2022

Initial experience and sizing considerations using the three lobed amplatzer ductal occluder.

David Meerkin1, Benjamin Farber, Amiram Nir

  • 1Director of Experimental Cardiology, Shaare Zedek Medical Center, POB 3235, Jerusalem, Israel. meerkin@SZMC.org.il

The Journal of Invasive Cardiology
|March 31, 2010
PubMed
Summary

The Amplatzer Ductal Occluder 2 (ADO2) device successfully closed patent ductus arteriosus (PDA) in pediatric patients. Initial results show promise for treating a wider range of PDA anatomies with this new device.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

Related Experiment Videos

Last Updated: Jun 14, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
10:52

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence

Published on: December 23, 2022

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

Area of Science:

  • Cardiovascular Interventions
  • Pediatric Cardiology
  • Medical Device Technology

Background:

  • The Amplatzer Ductal Occluder 2 (ADO2) is a novel device designed for patent ductus arteriosus (PDA) closure.
  • It targets small children with moderate shunts and larger children with small PDAs.

Observation:

  • Seven patients (median age 3y 4mo) underwent successful PDA closure using the ADO2.
  • Procedures utilized transpulmonary (6/7) and transaortic (1/7) approaches.
  • Device sizing was based on aortography, with a single case of recurrent patency at 24 hours.

Findings:

  • The ADO2 demonstrated successful PDA closure in a diverse pediatric age and weight range.
  • A single case showed recurrent patency at 24 hours, with complete occlusion at 1 month.
  • Device-specific length assessment led to shorter than recommended device selection.

Implications:

  • The ADO2 expands treatment options for PDA, offering simplicity and safety.
  • Device flexibility and alternative deployment enhance treatment ease in small patients and specific ductal anatomies.
  • Further research is needed to optimize device selection and confirm long-term outcomes.